After an extremely light March consisting of only seven IPOs coming to market, it was a sigh of relief for new issues investors to see the number of filings come in Monday morning before the market opened. Since the market closed Thursday, a total of six deals set terms:
- Carbylan Therapeutics
- Kempharm
- Aduro Biotech
- Cidara Therapeutics
- Virtu Financial
- PartyCity Holdco
- Opgen
On top of these six deals, the Etsy IPO is still on tap for next week. We wrote an article when the filing came out with the latest financials from this company. Checking back in on the deal, $ETSY is getting early press.
One interesting nugget from Etsy, they may be going public but they have warned investors they are not losing their ‘nice-guy’ image. USA Today has that story. Bloomberg adds that Wall Street may be weary over a company that cares about other items besides the bottom line.
To expand more on that note, Etsy was established as a B-Corp in 2012. It was something the company was/is proud of and blogged about. That title means the company met certain social, environmental, transparency and accountability standards. Additionally, B-Corp’s make a commitment to consider the interests of its stake holders, not just its shareholders. According to MarketWatch, $ETSY is the largest B-Corp to go through the IPO process. While the company is not profitable, it is not the first (or the last) to go through the process while earnings are in the red.
As for many IPOs, large institutional investors will likely be a large indicator in the demand for this IPO. Take the guessing game out of indicating for an IPO and subscribe to our service to get real time color on IPO and secondary deals each week.